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Abstract
Background: Indications for performing a prophylactic central neck dissection (pCND) in papillary thyroid cancer
(PTC) remain controversial. It is unclear how identification of lymph node (LN) metastases should impact the
decision to treat with radioactive iodine (RAI). The goals of this study were to identify indications for performing
pCND and identify factors that predict the use of adjuvant RAI.
Methods: This was a population based cross-sectional analysis. A prospectively collected database identified 594
patients who underwent total thyroidectomy +/− CND. A multivariate model was constructed to identify indications for
pCND and predictors of the use of RAI.
Results: 425 CNDs were performed of which 224 were prophylactic. Conventional risk factors (age, tumor size, extra-
thyroidal extension) were not associated with performing a pCND. The presence of clinically suspicious lymphadenopathy
was the only factor associated with performing CND, thus rendering the CND therapeutic. Positive LNs were retrieved in
39 % of pCND’s, upstaging 87 patients. Among all peri-operative predictors of receiving RAI, presence of LN metastases
was the strongest predictor [OR = 5.9 (3.7–9.5)], while tumor size was a modest predictor [OR = 1.8 (1.5–2.1)].
Other conventional risk factors did not predict use of adjuvant RAI.
Conclusions: Conventional risk factors were not indications for performing a pCND, implying that the decision
was based on individual surgeon preference. Performing pCND upstaged 39 % of patients from cN0 to pN1a,
increasing the likelihood of receiving RAI 6-fold. Conventional risk factors were not predictors of receiving
adjuvant RAI. This highlights the need for a unified approach to performing a pCND and administering RAI.
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Background
Central neck dissection (CND) has an important, but
controversial role in the treatment of papillary thyroid
cancer (PTC). The central neck is the first nodal basin
to which PTC spreads and when central neck nodes are
affected, between 20 and 90 % of patients develop lateral
neck compartment metastases [1, 2]. Therapeutic CND
(tCND) in patients with clinically suspicious lymph node
(LN) metastases is a well-established intervention. It is
when patients have no clinically suspicious metastatic
LNs that the role of prophylactic CND (pCND) becomes
unclear. The American Thyroid Association (ATA) 2015
guidelines identify that the impact of pCND on survival
is unclear, given that the survival in these patients is ex-
cellent overall [1, 3].
The 2009 ATA guideline recommended consideration
of a pCND on those who have advanced primary tumors
(T3 or T4), clinically involved lateral neck nodes (cN1b),
or if the information will be used to plan further steps in
therapy [1]. Following the publication of these guidelines,
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there was much debate in the surgical community as to
the value of pCND in all or even in high risk PTC patients.
Metastatic central compartment LN’s have been shown to
be associated with risk factors such as gender, primary
tumor size, BRAF mutations, primary extrathyroidal
extension and evidence of lateral cervical LN metastases,
leading some authors to utilize these features as indica-
tions for performing a pCND [4–6]. Small studies dem-
onstrated that cervical LN metastases may affect overall
survival in well differentiated thyroid cancer (WDTC)
[7, 8]. In contrast, however, other large epidemiologic
studies do not support the impact of performing a
pCND on survival [9, 10]. A recent randomized con-
trolled trial looking at the use of pCND in PTC showed
undergoing pCND required fewer repeat doses of radio-
active iodine (RAI), but significantly higher rates of
permanent hypoparathyroidism [11]. The conflicting
nature of the data led most surgeons to devise personal
algorithms for when to perform a pCND, as well as the
extent of the pCND (unilateral vs. bilateral CND).
Therefore, the objective of this study was to identify
the pre-operative indications associated with performing
a pCND among surgeons in the province of Alberta. We
hypothesized that surgical decision-making was consist-
ent with the ATA guidelines, with high-risk factors such
as advanced age, larger primary tumor and evidence of
extrathyroidal extension influencing a surgeon to per-
form a pCND. The second goal of this study was to de-
termine predictors of receiving adjuvant RAI. We
hypothesized that conventional risk factors would pre-
dict the use of RAI.
Methods
Thyroid surgeons in the province of Alberta have the
ability to record pre- and intra-operative data pertaining
to patients undergoing thyroid surgery using a prospect-
ively collected synoptic operative reporting system,
known as the Alberta WebSMR. [12] The resulting data
includes pre-operative parameters such as demograph-
ics, pre-operative staging, and evidence of any clinically
suspicious LNs in the neck. It also contains peri-
operative information such as size of the tumor, intra-
operative findings, and intra-operative complications.
This database was used to identify our patient cohort,
and to provide pre-operative and peri-operative data.
All patients identified via the Alberta WebSMR database
with a diagnosis of PTC who underwent, at minimum,
completion or total thyroidectomy, with or without CND
between January 1, 2009 and July 31, 2012 were included
for analysis. Patient demographic data including gender
and age were collected. Surgical data such as stage of can-
cer, type of surgery performed, extent of CND (unilateral
vs. bilateral) and evidence of extrathyroidal extension were
also collected. Pathology reports were reviewed to collect
overall LN yield, number of pathologic LNs identified in
the neck dissection sample, and final pathologic stage.
The use and dosage of RAI was also recorded.
Statistical analysis
Patient demographics, as well as pre-operative and intra-
operative variables were compared between those who
did and did not receive CND to determine associations
between these factors and performing a CND. Categor-
ical variables were compared using either a chi square
or Fisher exact test as appropriate, while continuous
variables were compared using either a Student’s t-test
or Wilcoxon rank-sum test as appropriate. A p-value of
less than or equal to 0.05 was deemed significant for all
analyses.
With respect to identifying factors that predicted the
use of RAI, a multivariable logistic regression model was
constructed using ‘high-risk’ predictors (from the litera-
ture) as well as those predictors that met with statistical
significance on univariate analysis. Odds ratios and
confidence intervals for significant predictors were cal-
culated. All final multivariable regression models were
evaluated for goodness-of fit, model stability and influ-
ential observations.
Statistical analysis was performed using Stata (version
12.1, StataCorp LP, College Station, TX).
This study was reviewed and approved by the Alberta
Cancer Research Ethics Committee.
Results
Table 1 illustrates demographic and tumor characteris-
tics, stratified by whether or not a patient underwent a
CND. In total, 594 patients treated by 18 surgeons
were included in our initial cohort. Of those, 425
(72 %) patients underwent CND. There were 313 uni-
lateral and 112 bilateral CND with mean total LN
yields of 7.4 +/− 6.3 nodes and 11.9 +/− 7.5 nodes re-
spectively. Of the 425 patients that underwent CND,
224 (53 %) underwent a pCND and 201 (47 %) a tCND.
In the 224 patients undergoing a pCND, none of the con-
ventional risk factors, such as pathologic tumor size, age,
or evidence of extrathyroidal extension were identified as
factors that influenced the decision to perform a pCND.
Overall, only the presence of pre-operative clinically suspi-
cious LNs was associated with a CND (p < 0.0001), thus
rendering the CND therapeutic.
Three hundred twenty-nine patients were identified
that had no preoperative suspicion of LNs in the central
neck, of which 224 (68 %) underwent a pCND and 87
(39 %) of these patients were found to have at least one
positive metastatic LN upon final pathologic evaluation.
Adjuvant RAI was then administered to 55 % of these 87
patients. Table 2 demonstrates the results of the multi-
variable logistic regression model among patients who
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had a clinical N0 neck. On multivariate analysis, T
stage was a modest predictor of receiving RAI [OR
1.83 (1.5–2.1)], while pathologic N Stage was the
strongest predictor [OR 5.9 (3.7–9.5)]. The act of perform-
ing a pCND was found to be collinear with pathologic N
stage, implying that performing a pCND increases the
likelihood of receiving adjuvant RAI, due to the high
chance of identification of LN metastases.
When stratifying patients based on number of
nodes retrieved, patients with greater than 5 positive
nodes were the most likely to receive RAI [OR = 23.3
(8.3, 65.3)], followed by patients with 1 to 5 nodes
identified [OR = 5.9 (3.8, 9.3)].
The flow chart in Fig. 1 demonstrates how a surgeon’s
decision to perform a prophylactic CND affects a pa-
tient’s management in our cohort. In the province of Al-
berta, 68 % of patients without clinical evidence of LN
metastasis received a pCND. After having performed the
pCND, occult LN metastasis would be discovered in
39 %, thus upstaging the patient. As a result of having
pathologically positive LNs, these patients are almost 6
times more likely to receive RAI.
Discussion
The role of pCND has become a much-debated topic
over the last several years. While there is little debate
about how to manage clinically apparent central LN me-
tastasis, the role of pCND is unclear [1–3]. A recent
meta-analysis concluded that performing routine pCND
increases the risk of temporary hypocalcaemia and does
not improve loco-regional control [10]. This would
argue that CND has some morbidity, but questionable
efficacy. However, CND can provide prognostic informa-
tion and influence the decision to administer RAI, lead-
ing some to advocate for more comprehensive staging
and risk stratification [3, 13]. Current literature reflects
that conventional risk factors such as age of patient,
tumor size, extrathyroidal invasion, and lateral neck dis-
ease are associated with a higher likelihood of occult dis-
ease in the central LN’s, and as such are utilized as
guidelines for performing a pCND [4–6].
In the initial analysis tumors were divided into six
categories based on T-stage, and there was no correl-
ation between tumor size and pCND. In order to en-
sure that our analysis was not limited by the fact that
some sub-categories of T-stage had a limited sample
size, a separate post-hoc analysis was performed by first
dichotomizing patients into only two groups based on
T – stage (T1-2 vs. T3-4). There was a non-significant
trend toward increased likelihood of pCND in the T3-4
group. We also dichotomized patients based on age
(age <45 vs. age >45) and again, found no association
between dichotomized age and pCND.
In contrast to what is assumed to be the reason behind
the adoption of pCND in Alberta following the publica-
tion of the ATA guidelines in 2009, we were unable to
identify any conventional risk factors that influenced the
decision to perform a pCND. Three-hundred-twenty-
nine patients had no suspicious nodes pre-operatively,
and in this subset, factors such as advanced tumor size,
age and evidence of extrathyroidal extension failed to
differentiate those who did receive a pCND from those
who did not. This deviation from the ATA demonstrates
Table 2 Logistic regression: Factors that predict administration
of adjuvant RAI
Predictor OR CI p-value
Pathologic T stage 1.83 1.5–2.1 0.0001
Pathologic N stage 5.9 3.7–9.5 0.0001
Age NS
ETE NS
RAI radioactive iodine ablation, ETE extrathyroidal extension
Table 1 Clinical and pathologic patient factors stratified by
whether patient received CND or not
No CND CND p value
No. of patients 169 425
Age (years) 46.3 45.6 ns
Sex
Male 43 100 ns
Female 126 325
Clinically suspicious lymph nodes in central neck
Yes 6 81 <0.0001
No 105 224
Procedure
Total Thyroidectomy or Completion
Thyroidectomy alone
169 0
Total Thyroidectomy with Ipsilateral CND 0 313
Total Thyroidectomy with Bilateral CND 0 112
T stage







M0 157 414 ns
M1 0 2
Tumor size (largest dimension in centimeters) 2.0 2.2 ns
Extrathyroidal Extension present 3 20 ns
CND central neck dissection, ns not significant
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that surgeons have developed a more surgeon-specific
approach to performing a CND.
A recent study by the ATA showed that the number of
pathologic LNs obtained in a CND may have more prog-
nostic significance than simply the presence of any LN
metastases [13]. This review found that prognosis chan-
ged only if 5 or more metastatic LNs were identified,
emphasizing the need to perform a comprehensive
CND. Previous work published by our group confirmed
that comprehensive CNDs are being performed across
our province [14]. It was the belief of the senior authors
that by providing better staging material, patients who
might otherwise have been candidates for adjuvant ther-
apy in the past could now be observed.
However this study demonstrated that the decision to
perform a pCND lead to a downstream decision to ad-
minister adjuvant therapy. The strongest predictor of re-
ceiving adjuvant RAI was the presence of LN metastasis
(pN stage), while tumor size (pT stage) was only a mod-
est predictor. In the province of Alberta, 68 % of patients
without clinical evidence of LN metastasis received a
pCND, whereby occult LN metastases were discovered
in 39 %, thus significantly upstaging the patient. In pa-
tients with pathologically positive LNs, the likelihood of
receiving RAI was almost 6 times higher. While the ad-
verse effects of RAI are relatively low, the potential
benefit from this intervention has not been clarified in
the intermediate-risk patient population with a limited
number of LN metastases. It is possible that a large
number of these patients are being over-treated with ad-
juvant RAI [15].
The new 2015 guidelines suggest that patients are con-
sidered low risk if they are clinically N0 or have ≤5
pathologic lymph nodes with micrometastasis (<0.2 cm
in largest dimension), whereas patients that are clinically
N1 or have >5 pathologic lymph nodes are considered
intermediate risk. Patients with intermediate level of risk
may derive some benefit from RAI. In our cohort, pa-
tients with greater than 5 positive nodes were the most
likely group to receive RAI. Despite the fact that our co-
hort was assembled prior to the release of these updated
guidelines, it would appear we are compliant with the
current risk stratification. With further improvements in
compliance to this proposed risk stratification, future pa-
tients may either be appropriately spared adjuvant RAI,
or may more clearly warrant the use of adjuvant RAI,
depending on risk level.
One limitation of this study is the variable compliance
among surgeons in using the Alberta WebSMR synoptic
reporting system. It is not mandatory for surgeons to
utilize this database, thus, our data represents the major-
ity, rather than the entirety, of thyroid procedures car-
ried out in the province. While it is possible that some
surgeons may be selective in which patients they enter
Fig. 1 Potential impact of performing prophylactic CND on patient with low-risk well differentiated thyroid cancer
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into the database, we believe that for those surgeons
who do enter patients into the database, all consecutive
patients are entered.
Although data for this study was collected over a short
3-year period, during this time endocrinologists in our
province began to use baseline, post-operative stimulated
thyroglobulin and low dose I131 whole body scans prior
to administration of therapeutic doses of RAI. Therefore,
it was not feasible to look at baseline stimulated thyro-
globulin and whole body scans as factors that may pre-
dict the use of RAI in our cohort. It is therefore possible
that there were other factors that influenced the admin-
istration of RAI then was analyzed.
This study is unique in that we were able to assess
practice patterns among surgeons from different institu-
tions and surgical disciplines. The homogeneity of the
large sample size selected from the provincial population
base of 3.6 million enables us to generalize our findings
beyond institutional borders and renders the evaluation
of a large number of independent predictors feasible.
This study highlights the lack of consensus across the
province both with respect to indications for performing
a pCND as well as for receiving adjuvant RAI. Although
the ATA guidelines are frequently referred to in address-
ing practice management, specialists in our province
were not uniform in adherence. Rather, specialists ap-
peared to develop individual, practice-based treatment
algorithms as it relates to performing a pCND and ad-
ministering RAI. With the recent publication of the
2015 ATA guidelines, refinement of the indications for
pCND, risk stratification and utilization of RAI adminis-
tration will need to be addressed within our provincial
group of specialists. While there is often a lag time in
guideline adherence, with the results from this study,
our group is now ideally situated to institute an inter-
vention that would improve consistency among special-
ists, and thus standardize treatment across the province.
Conclusions
Indications for performing a pCND appear to vary among
surgeons across the province, and were not always consist-
ent with conventional risk factors for high risk PTC. Cur-
rently, the only consistent factor that influences the
decision to perform a CND is the presence of clinically de-
tected suspicious lymphadenopathy. In the setting where
no pre-operative suspicious nodes were apparent, 39 % of
patients who underwent pCND had their nodal status
upstaged and in these patients, the likelihood of receiving
adjuvant RAI was increased 6-fold because of the identifi-
cation of one or more metastatic LNs.
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